Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register
Objectives To compare the effectiveness of adding synthetic disease-modifying antirheumatic drugs (sDMARDs) versus tumour necrosis factor α inhibitors (TNFi) to methotrexate (MTX) in patients with rheumatoid arthritis (RA) who were MTX inadequate responders (IR). Second, to examine outcomes in patie...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2011-12, Vol.70 (12), p.2103-2110 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2110 |
|---|---|
| container_issue | 12 |
| container_start_page | 2103 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 70 |
| creator | Lie, Elisabeth van der Heijde, Désirée Uhlig, Till Mikkelsen, Knut Kalstad, Synøve Kaufmann, Cecilie Rødevand, Erik Kvien, Tore K |
| description | Objectives To compare the effectiveness of adding synthetic disease-modifying antirheumatic drugs (sDMARDs) versus tumour necrosis factor α inhibitors (TNFi) to methotrexate (MTX) in patients with rheumatoid arthritis (RA) who were MTX inadequate responders (IR). Second, to examine outcomes in patients receiving MTX+TNFi for whom the MTX+sDMARD combination had also failed. Methods Patients with RA (disease duration ≤ 5 years, MTX IR and naïve to other DMARDs) starting treatment with MTX+TNFi or MTX+sDMARDs were included. From the latter group a subgroup of patients who went on to receive MTX+TNFi was identified. Results Patients receiving MTX+TNFi (n=98) and MTX+sDMARDs (n=129) had similar baseline disease activity when starting combination therapy (mean Disease Activity Score 28 (DAS28) = 4.90 and 4.96, respectively). Three- and 6-month effectiveness and 2-year drug survival were better for MTX+TNFi than for MTX+sDMARDs: mean ∆DAS28 was −1.61 versus −0.85 after 3 months (p |
| doi_str_mv | 10.1136/ard.2011.152363 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902329895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4009192641</sourcerecordid><originalsourceid>FETCH-LOGICAL-b427t-9b31ed567f9f0e658e7c076abf74df62423d98c34db11099448ca70462ccbc513</originalsourceid><addsrcrecordid>eNqF0ctu1DAUBuAIgehQWLNDlhBCQsrUt_jCrkyhIJUWqsKCjeU4DvGQxIPtqO0j8NY4ylAkNqws2985x_JfFE8RXCNE2JEOzRpDhNaowoSRe8UKUSZKDBm8X6wghKSkkvGD4lGM27yFAomHxQFGgleC01Xx6ypYnQY7JhBT0Ml-dzYCN4KdTi6fRnDtUgdCZ6dBJ-8aoEPqgksugtYHcN35AQw2dT4Fe5PrweBHnzob9O4WdDor7XrbvAaNThq0IfN8C84vLsuTj8eXJyDkkTHZ8Lh40Oo-2if79bD48u7t1eZ9eXZx-mFzfFbWFPNUypog21SMt7KFllXCcgM503XLadMyTDFppDCENjVCUEpKhdEcUoaNqU2FyGHxcum7C_7nZGNSg4vG9r0erZ-ikhATLIWssnz-j9z6KYz5cQpxLqAklZjV0aJM8DEG26pdcIMOtwpBNYekckhqDkktIeWKZ_u-Uz3Y5s7_SSWDF3ugo9F9G_RoXPzrKK8QxCK7cnHzB97c3evwQzFOeKXOv27U6Tfyib2hn9U8-NXi62H731f-BkU3t08</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778093585</pqid></control><display><type>article</type><title>Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Lie, Elisabeth ; van der Heijde, Désirée ; Uhlig, Till ; Mikkelsen, Knut ; Kalstad, Synøve ; Kaufmann, Cecilie ; Rødevand, Erik ; Kvien, Tore K</creator><creatorcontrib>Lie, Elisabeth ; van der Heijde, Désirée ; Uhlig, Till ; Mikkelsen, Knut ; Kalstad, Synøve ; Kaufmann, Cecilie ; Rødevand, Erik ; Kvien, Tore K</creatorcontrib><description>Objectives To compare the effectiveness of adding synthetic disease-modifying antirheumatic drugs (sDMARDs) versus tumour necrosis factor α inhibitors (TNFi) to methotrexate (MTX) in patients with rheumatoid arthritis (RA) who were MTX inadequate responders (IR). Second, to examine outcomes in patients receiving MTX+TNFi for whom the MTX+sDMARD combination had also failed. Methods Patients with RA (disease duration ≤ 5 years, MTX IR and naïve to other DMARDs) starting treatment with MTX+TNFi or MTX+sDMARDs were included. From the latter group a subgroup of patients who went on to receive MTX+TNFi was identified. Results Patients receiving MTX+TNFi (n=98) and MTX+sDMARDs (n=129) had similar baseline disease activity when starting combination therapy (mean Disease Activity Score 28 (DAS28) = 4.90 and 4.96, respectively). Three- and 6-month effectiveness and 2-year drug survival were better for MTX+TNFi than for MTX+sDMARDs: mean ∆DAS28 was −1.61 versus −0.85 after 3 months (p<0.001) and −1.91 versus −1.03 after 6 months (p=0.01); DAS28<2.6 was reached by 29.0% versus 11.6% after 3 and 34.5% versus 12.9% after 6 months. Effectiveness was somewhat better with triple therapy than other MTX+sDMARD combinations but was generally inferior compared with MTX+TNFi. For the patients who received MTX+TNFi as a third step after MTX+sDMARDs had failed (n=38) there was a tendency towards lower remission rates, worse disease activity states and inferior drug survival compared with patients who received MTX+TNFi directly after the failure of MTX. Conclusions Effectiveness was better for MTX+TNFi than for MTX+sDMARDs. Patients who started MTX+TNFi after two synthetic DMARD regimens had failed had a tendency to less favourable disease states after 3 months than patients who switched directly from MTX to MTX+TNFi.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2011.152363</identifier><identifier>PMID: 21875874</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Disease ; Diseases of the osteoarticular system ; Drug Substitution ; Drug Therapy, Combination ; Epidemiologic Methods ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Inflammatory joint diseases ; Male ; Medical sciences ; Medication Adherence ; Methotrexate - therapeutic use ; Middle Aged ; Patients ; Performance evaluation ; Pharmacology. Drug treatments ; Regression analysis ; Remission (Medicine) ; Rheumatoid arthritis ; Rheumatology ; Survival analysis ; Treatment Failure ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor necrosis factor-TNF</subject><ispartof>Annals of the rheumatic diseases, 2011-12, Vol.70 (12), p.2103-2110</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b427t-9b31ed567f9f0e658e7c076abf74df62423d98c34db11099448ca70462ccbc513</citedby><cites>FETCH-LOGICAL-b427t-9b31ed567f9f0e658e7c076abf74df62423d98c34db11099448ca70462ccbc513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/70/12/2103.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/70/12/2103.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24751028$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21875874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lie, Elisabeth</creatorcontrib><creatorcontrib>van der Heijde, Désirée</creatorcontrib><creatorcontrib>Uhlig, Till</creatorcontrib><creatorcontrib>Mikkelsen, Knut</creatorcontrib><creatorcontrib>Kalstad, Synøve</creatorcontrib><creatorcontrib>Kaufmann, Cecilie</creatorcontrib><creatorcontrib>Rødevand, Erik</creatorcontrib><creatorcontrib>Kvien, Tore K</creatorcontrib><title>Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives To compare the effectiveness of adding synthetic disease-modifying antirheumatic drugs (sDMARDs) versus tumour necrosis factor α inhibitors (TNFi) to methotrexate (MTX) in patients with rheumatoid arthritis (RA) who were MTX inadequate responders (IR). Second, to examine outcomes in patients receiving MTX+TNFi for whom the MTX+sDMARD combination had also failed. Methods Patients with RA (disease duration ≤ 5 years, MTX IR and naïve to other DMARDs) starting treatment with MTX+TNFi or MTX+sDMARDs were included. From the latter group a subgroup of patients who went on to receive MTX+TNFi was identified. Results Patients receiving MTX+TNFi (n=98) and MTX+sDMARDs (n=129) had similar baseline disease activity when starting combination therapy (mean Disease Activity Score 28 (DAS28) = 4.90 and 4.96, respectively). Three- and 6-month effectiveness and 2-year drug survival were better for MTX+TNFi than for MTX+sDMARDs: mean ∆DAS28 was −1.61 versus −0.85 after 3 months (p<0.001) and −1.91 versus −1.03 after 6 months (p=0.01); DAS28<2.6 was reached by 29.0% versus 11.6% after 3 and 34.5% versus 12.9% after 6 months. Effectiveness was somewhat better with triple therapy than other MTX+sDMARD combinations but was generally inferior compared with MTX+TNFi. For the patients who received MTX+TNFi as a third step after MTX+sDMARDs had failed (n=38) there was a tendency towards lower remission rates, worse disease activity states and inferior drug survival compared with patients who received MTX+TNFi directly after the failure of MTX. Conclusions Effectiveness was better for MTX+TNFi than for MTX+sDMARDs. Patients who started MTX+TNFi after two synthetic DMARD regimens had failed had a tendency to less favourable disease states after 3 months than patients who switched directly from MTX to MTX+TNFi.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Disease</subject><subject>Diseases of the osteoarticular system</subject><subject>Drug Substitution</subject><subject>Drug Therapy, Combination</subject><subject>Epidemiologic Methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Inflammatory joint diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Pharmacology. Drug treatments</subject><subject>Regression analysis</subject><subject>Remission (Medicine)</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Survival analysis</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0ctu1DAUBuAIgehQWLNDlhBCQsrUt_jCrkyhIJUWqsKCjeU4DvGQxIPtqO0j8NY4ylAkNqws2985x_JfFE8RXCNE2JEOzRpDhNaowoSRe8UKUSZKDBm8X6wghKSkkvGD4lGM27yFAomHxQFGgleC01Xx6ypYnQY7JhBT0Ml-dzYCN4KdTi6fRnDtUgdCZ6dBJ-8aoEPqgksugtYHcN35AQw2dT4Fe5PrweBHnzob9O4WdDor7XrbvAaNThq0IfN8C84vLsuTj8eXJyDkkTHZ8Lh40Oo-2if79bD48u7t1eZ9eXZx-mFzfFbWFPNUypog21SMt7KFllXCcgM503XLadMyTDFppDCENjVCUEpKhdEcUoaNqU2FyGHxcum7C_7nZGNSg4vG9r0erZ-ikhATLIWssnz-j9z6KYz5cQpxLqAklZjV0aJM8DEG26pdcIMOtwpBNYekckhqDkktIeWKZ_u-Uz3Y5s7_SSWDF3ugo9F9G_RoXPzrKK8QxCK7cnHzB97c3evwQzFOeKXOv27U6Tfyib2hn9U8-NXi62H731f-BkU3t08</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Lie, Elisabeth</creator><creator>van der Heijde, Désirée</creator><creator>Uhlig, Till</creator><creator>Mikkelsen, Knut</creator><creator>Kalstad, Synøve</creator><creator>Kaufmann, Cecilie</creator><creator>Rødevand, Erik</creator><creator>Kvien, Tore K</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register</title><author>Lie, Elisabeth ; van der Heijde, Désirée ; Uhlig, Till ; Mikkelsen, Knut ; Kalstad, Synøve ; Kaufmann, Cecilie ; Rødevand, Erik ; Kvien, Tore K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b427t-9b31ed567f9f0e658e7c076abf74df62423d98c34db11099448ca70462ccbc513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Disease</topic><topic>Diseases of the osteoarticular system</topic><topic>Drug Substitution</topic><topic>Drug Therapy, Combination</topic><topic>Epidemiologic Methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Inflammatory joint diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Pharmacology. Drug treatments</topic><topic>Regression analysis</topic><topic>Remission (Medicine)</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Survival analysis</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lie, Elisabeth</creatorcontrib><creatorcontrib>van der Heijde, Désirée</creatorcontrib><creatorcontrib>Uhlig, Till</creatorcontrib><creatorcontrib>Mikkelsen, Knut</creatorcontrib><creatorcontrib>Kalstad, Synøve</creatorcontrib><creatorcontrib>Kaufmann, Cecilie</creatorcontrib><creatorcontrib>Rødevand, Erik</creatorcontrib><creatorcontrib>Kvien, Tore K</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lie, Elisabeth</au><au>van der Heijde, Désirée</au><au>Uhlig, Till</au><au>Mikkelsen, Knut</au><au>Kalstad, Synøve</au><au>Kaufmann, Cecilie</au><au>Rødevand, Erik</au><au>Kvien, Tore K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>70</volume><issue>12</issue><spage>2103</spage><epage>2110</epage><pages>2103-2110</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives To compare the effectiveness of adding synthetic disease-modifying antirheumatic drugs (sDMARDs) versus tumour necrosis factor α inhibitors (TNFi) to methotrexate (MTX) in patients with rheumatoid arthritis (RA) who were MTX inadequate responders (IR). Second, to examine outcomes in patients receiving MTX+TNFi for whom the MTX+sDMARD combination had also failed. Methods Patients with RA (disease duration ≤ 5 years, MTX IR and naïve to other DMARDs) starting treatment with MTX+TNFi or MTX+sDMARDs were included. From the latter group a subgroup of patients who went on to receive MTX+TNFi was identified. Results Patients receiving MTX+TNFi (n=98) and MTX+sDMARDs (n=129) had similar baseline disease activity when starting combination therapy (mean Disease Activity Score 28 (DAS28) = 4.90 and 4.96, respectively). Three- and 6-month effectiveness and 2-year drug survival were better for MTX+TNFi than for MTX+sDMARDs: mean ∆DAS28 was −1.61 versus −0.85 after 3 months (p<0.001) and −1.91 versus −1.03 after 6 months (p=0.01); DAS28<2.6 was reached by 29.0% versus 11.6% after 3 and 34.5% versus 12.9% after 6 months. Effectiveness was somewhat better with triple therapy than other MTX+sDMARD combinations but was generally inferior compared with MTX+TNFi. For the patients who received MTX+TNFi as a third step after MTX+sDMARDs had failed (n=38) there was a tendency towards lower remission rates, worse disease activity states and inferior drug survival compared with patients who received MTX+TNFi directly after the failure of MTX. Conclusions Effectiveness was better for MTX+TNFi than for MTX+sDMARDs. Patients who started MTX+TNFi after two synthetic DMARD regimens had failed had a tendency to less favourable disease states after 3 months than patients who switched directly from MTX to MTX+TNFi.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>21875874</pmid><doi>10.1136/ard.2011.152363</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2011-12, Vol.70 (12), p.2103-2110 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902329895 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Disease Diseases of the osteoarticular system Drug Substitution Drug Therapy, Combination Epidemiologic Methods Female Humans Immunosuppressive Agents - therapeutic use Inflammatory joint diseases Male Medical sciences Medication Adherence Methotrexate - therapeutic use Middle Aged Patients Performance evaluation Pharmacology. Drug treatments Regression analysis Remission (Medicine) Rheumatoid arthritis Rheumatology Survival analysis Treatment Failure Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF |
| title | Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A24%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20strategies%20in%20patients%20with%20rheumatoid%20arthritis%20for%20whom%20methotrexate%20monotherapy%20has%20failed:%20data%20from%20the%20NOR-DMARD%20register&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Lie,%20Elisabeth&rft.date=2011-12-01&rft.volume=70&rft.issue=12&rft.spage=2103&rft.epage=2110&rft.pages=2103-2110&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2011.152363&rft_dat=%3Cproquest_cross%3E4009192641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778093585&rft_id=info:pmid/21875874&rfr_iscdi=true |